Impact of the nature and size of the polymeric backbone on the ability of heterobifunctional ligands to mediate Shiga toxin and serum amyloid P component ternary complex formation

Toxins

Volumn 3, Issue 9, 2011, Pages 1065-1088

  Kitov, Pavel I ^a   Paszkiewicz, Eugenia ^a   Sadowska, Joanna M ^a   Deng, Zhicheng ^b   Ahmed, Marya ^b   Narain, Ravin ^b   Griener, Thomas P ^c   Mulvey, George L ^c   Armstrong, Glen D ^c   Bundle, David R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

E. coli O157:H7; Gb3; Multivalent inhibitors; Pk trisaccharide

Indexed keywords

1,2 O [1 (CARBOXY)ETHYLIDENE] 4 O (BETA DEXTRO GALACTOPYRANOSYL) 6 O (10 OXO 3,6,11 TRIOXA 9 AZATETRADEC 13 YNYL)CARBAMOYL ALPHA DEXTRO GLUCOPYRANOSIDE; 1,2 O [1 (CARBOXY)ETHYLIDENE] 4 O [4 O (ALPHA DEXTRO GALACTOPYRANOSYL) BETA DEXTRO GALACTOPYRANOSYL] 6 O (10 OXO 3,6,11 TRIOXA 9 AZATETRADEC 13 YNYL)CARBAMOYL ALPHA DEXTRO GLUCOPYRANOSIDE; 3 O ACETYL 6 O (10 OXO 3,6,11 TRIOXA 9 AZATETRADEC 13 YNYL)CARBAMOYL 4 O (2,3,4,6 TETRA O ACETYL BETA DEXTRO GALACTOPYRANOSYL) 1,2 O [1 (METHOXYCARBONYL)ETHYLIDENE] ALPHA DEXTRO GLUCOPYRANOSIDE; 4 NITROPHENYL 2 [2 [2 (PROP 2 YNYLOXY)ETHOXY]ETHOXY]ETHYL CARBONATE; 5 (3 AZIDO 2 HYDROXYPROPOXY) N,N,2 TRIMETHYL 1,3 DIOXANE 2 CARBOXAMIDE; 5 [2 [ALPHA DEXTRO GALACTOPYRANOSYL (1-4) BETA DEXTRO GALACTOPYRANOSYL (1-4) BETA DEXTRO GLUCOPYRANOSYLOXY] 5 OXO 6,9,12,15 TETRAOXO 4 AZAOCTADEC 17 YNYLOXY] 2 METHYL 1,3 DIOXANE 2 CARBOXYLIC ACID; 5 [2 [BETA DEXTRO GALACTOPYRANOSYL (1-4) BETA DEXTRO GLUCOPYRANOSYLOXY] 5 OXO 6,9,12,15 TETRAOXA 4 AZAOCTADEC 17 YNYLOXY] 2 METHYL 1,3 DIOXANE 2 CARBOXYLIC ACID; 5 [3 (PROP 2 YN)OXYCARBONYLAMINO 2 [4 (BETA DEXTRO GALACTOPYRANOSYL) BETA DEXTRO GLUCOPYRANOSYLOXY]PROPOXY] 2 METHYL 1,3 DIOXANE 2 CARBOXYLIC ACID; 5 [3 (PROP 2 YN)OXYCARBONYLAMINO 2 [ALPHA DEXTRO GALACTOPYRANOSYL (1-4) BETA DEXTRO GALACTOPYRANOSYL (1-4) BETA DEXTRO GLUCOPYRANOSYLOXY]PROPOXY] 2 METHYL 1,3 DIOXANE 2 CARBOXYLIC ACID; 5 [3 ACETAMIDO 2 [2,3,6 TRI O ACETYL 4 (2,3,4,6 TETRA O ACETYL BETA DEXTRO GALACTOPYRANOSYL) BETA DEXTRO GLUCOPYRANOSYLOXY]PROPOXY] N,N,2 TRIMETHYL 1,3 DIOXANE 2 CARBOXAMIDE; 5 [3 AZIDO 2 [2,3,6 TRI O ACETYL 4 (2,3,4,6 TETRA O ACETYL BETA DEXTRO GALACTOPYRANOSYL) BETA DEXTRO GLUCOPYRANOSYLOXY]PROPOXY] N,N,2 TRIMETHYL 1,3 DIOXANE 2 CARBOXAMIDE; ANTIINFECTIVE AGENT; N [3 (TERT BUTYLOXYCARBONYLAMINO)PROPYL]METHACRYLAMIDE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYACRYLAMIDE; POLYMER BOUND HETEROBIFUNCTIONAL INHIBITOR ADAPTOR; PROP 2 YNYL 2 [2 (2 TERT BUTYLOXYCARBONYLAMINOETHOXY)ETHOXY]ETHYLCARBAMATE; SERUM AMYLOID P; TERT BUTYL 2 [2 [(4 NITROPHENOXY)CARBONYLOXY]ETHOXY]ETHYLCARBAMATE; UNCLASSIFIED DRUG; VEROTOXIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; HOST CELL; IN VIVO STUDY; INTOXICATION; MOLECULAR RECOGNITION; MOLECULAR SIZE; MOUSE; NONHUMAN; POLYMERIZATION; PROTECTION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; VERO CELL;

ACRYLAMIDES; ACRYLIC RESINS; ANIMALS; CELL SURVIVAL; LIGANDS; MICE; MICE, TRANSGENIC; SERUM AMYLOID P-COMPONENT; SHIGA TOXIN; VERO CELLS;

BACTERIA (MICROORGANISMS);

EID: 80053216684     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins3091065     Document Type: Article

References (36)

1. Griffin, P.M. Escherichia coli O157:H7 and Other Enterohemorrhagic Escherichia coli. In Infections of the gastrointestinal tract; Raven Press: Newyork, UK, USA, 1995, pp. 739-761.
2. Karch, H.; Tarr, P.I.; Blelaszewska, M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 2005, 295, 405-418.
3. Wong, C.S.; Jelacic, S.; Habeeb, R.L.; Watkins, S.L.; Tarr, P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. N. Engl. J. Med. 2000, 342, 1930-1936.
4. Dundas, S.; Todd, W.T.A.; Stewart, A.I.; Murdoch, P.S.; Chaudhuri, A.K.R.; Hutchinson, S.J. The central Scotland Escherichia coli O157: H7 outbreak: Risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 2001, 33, 923-931.
5. Trachtman, H.; Cnaan, A.; Christen, E.; Gibbs, K.; Zhao, S.Y.; Acheson, D.W.K.; Weiss, R.; Kaskel, F.J.; Spitzer, A.; Hirschman, G.H. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children-A randomized controlled trial. J. Am. Med. Assoc. 2003, 290, 1337-1344.
6. Nakao, H.; Kataoka, C.; Kiyokawa, N.; Fujimoto, J.; Yamasaki, S.; Takeda, T. Monoclonal antibody to Shiga toxin 1, which blocks receptor binding and neutralizes cytotoxicity. Microbiol. Immunol. 2002, 46, 777-780.
7. Nakao, H.; Kiyokawa, N.; Fujimoto, J.; Yamasaki, S.; Takeda, T. Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity. Infect. Immun. 1999, 67, 5717-5722.
8. Lopez, E.L.; Contrini, M.M.; Glatstein, E.; Ayala, S.G.; Santoro, R.; Allende, D.; Ezcurra, G.; Teplitz, E.; Koyama, T.; Matsumoto, Y.; Sato, H.; Sakai, K.; Hoshide, S.; Komoriya, K.; Morita, T.; Harning, R.; Brookman, S. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob. Agents Chemother. 2010, 54, 239-243.
9. Nishikawa, K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli. Arch. Immunol. Ther. Exp. (Warsz) 2011, 59, 239-247.
10. Stechmann, B.; Bai, S.-K.; Gobbo, E.; Lopez, R.; Merer, G.; Pinchard, S.; Panigai, L.; Tenza, D.; Raposo, G.; Beaumelle, B.; Sauvaire, D.; Gillet, D.; Johannes, L.; Barbier, J. Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 2010, 141, 231-242.
11. Kitov, P.; Mulvey, G.; Griener, T.; Lipinski, T.; Solomon, D.; Paszkiewicz, E.; Jacobson, J.; Sadowska, J.; Suzuki, M.; Yamamura, K.; Armstrong, G.; Bundle, D. In vivo supramolecular templating enhances the activity of multivalent ligands: A potential therapeutic against the Escherichia coli O157 AB(5) toxins. Proc. Natl. Acad. Sci. USA 2008, 105, 16837-16842.
12. Suzuki, T.; Hisakawa, S.; Itoh, Y.; Suzuki, N.; Takahashi, K.; Kawahata, M.; Yamaguchi, K.; Nakagawa, H.; Miyata, N. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4208-4212.
13. Solomon, D.; Kitov, P.I.; Paszkiewicz, E.; Grant, G.A.; Sadowska, J.M.; Bundle, D.R. Heterobifunctional multivalent inhibitor-adaptor mediates specific aggregation between Shiga toxin and a pentraxin. Org. Lett. 2005, 7, 4369-4372.
14. Li, H.; Li, Q.; Cai, M.; Li, Z. Synthesis of galactosyl and lactosyl derivatives as potential anti-metastasis compounds. Carbohydr. Res. 2000, 328, 611-615.
15. Lu, G.; Lam, S.; Burgess, K. An iterative route to "decorated" ethylene glycol-based linkers. Chem. Commun. 2006, 1652-1654.
16. Klein, E.; DeBonis, S.; Thiede, B.; Skoufias, D.; Kozielski, F.; Lebeau, L. New chemical tools for investigating human mitotic kinesin Eg5. Bioorg. Med. Chem. 2007, 15, 6474-6488.
17. Goddard-Borger, E.D.; Stick, R.V. An efficient, inexpensive, and shelf-stable diazotransfer reagent: Imidazole-1-sulfonyl azide hydrochloride. Org. Lett. 2011, 13, 2514-2514;
18. Kitov, P.; Sadowska, J.; Mulvey, G.; Armstrong, G.; Ling, H.; Pannu, N.; Read, R.; Bundle, D. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000, 403, 669-672.
19. Kitov, P.; Lipinski, T.; Paszkiewicz, E.; Solomon, D.; Sadowska, J.; Grant, G.; Mulvey, G.; Kitova, E.; Klassen, J.; Armstrong, G.; Bundle, D. An entropically efficient supramolecular inhibition strategy for Shiga toxins. Angew. Chem. Inter. Ed. 2008, 47, 672-676.
20. Zhao, X.; Araki, K.; Miyazaki, J.; Yamamura, K. Developmental and liver-specific expression directed by the serum amyloid-p component promoter in transgenic mice. J. Biochem. 1992, 111, 736-738.
21. Kitov, P.I.; Paszkiewicz, E.; Wakarchuk, W.W.; Bundle, D.R. Preparative-scale chemoenzymatic synthesis of large carbohydrate assemblies using alpha(1-4)galactosyltransferase/UDP-4'-Gal-epimerase fusion protein. in Recognition of Carbohydrates in Biological Systems Pt a: General Procedures 2003, 362, 86-105.
22. Gestwicki, J.E.; Crabtree, G.R.; Graef, I.A. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004, 306, 865-869.
23. Bertozzi, C.R.; Bednarski, M.D. Antibody targeting to bacterial-cells using receptor-specific ligands. J. Am. Chem. Soc. 1992, 114, 2242-2245.
24. Shokat, K.M.; Schultz, P.G. Redirecting the immune-response-ligand-mediated immunogenicity. J. Am. Chem. Soc. 1991, 113, 1861-1862.
25. O'Reilly, M.K.; Collins, B.E.; Han, S.; Liao, L.; Rillahan, C.; Kitov, P.I.; Bundle, D.R.; Paulson, J.C. Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. J. Am. Chem. Soc. 2008, 130, 7736-7745.
26. Cui, L.; Kitov, P.I.; Completo, G.C.; Paulson, J.C.; Bundle, D.R. Supramolecular complexing of membane siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM. Bioconjugate Chem. 2011, 22, 546-550.
27. Sprincl, L.; Exner, J.; Sterba, O.; Kopecek, J. New types of synthetic infusion solutions. 3. Elimination and retention of poly n-(2-hydroxypropyl)methacrylamide in a test organism. J. Biomed. Mater. Res. 1976, 10, 953-963.
28. Sterba, O.; Uhlirova, Z.; Petz, R.; Viktora, L.; Jirasek, A.; Kopecek, J. Duxon-A new Czechoslovak-made infusion solution-An experimental contribution to biological evaluation. Cas. Lek. Cesk. 1980, 119, 994-997.
29. Ulbrich, K.; Subr, V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv. Drug Deliv. Rev. 2010, 62, 150-166.
30. Yanjarappa, M.J.; Gujraty, K.V.; Joshi, A.; Saraph, A.; Kane, R.S. Synthesis of copolymers containing an active ester of methacrylic acid by RAFT: Controlled molecular weight scaffolds for biofunctionalization. Biomacromolecules 2006, 7, 1665-1670.
31. Liu, X.M.; Quan, L.D.; Tian, J.; Alnouti, Y.; Fu, K.; Thiele, G.M.; Wang, D. Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm. Res. 2008, 25, 2910-2919.
32. Herth, M.M.; Barz, M.; Moderegger, D.; Allmeroth, M.; Jahn, M.; Thews, O.; Zentel, R.; Rosch, F. Radioactive labeling of defined HPMA-based polymeric structures using F-18 FETos for in vivo imaging by positron emission tomography. Biomacromolecules 2009, 10, 1697-1703.
33. Ling, H.; Boodhoo, A.; Hazes, B.; Cummings, M.D.; Armstrong, G.D.; Brunton, J.L.; Read, R.J. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb(3). Biochemistry 1998, 37, 1777-1788.
34. Soltyk, A.M.; MacKenzie, C.R.; Wolski, V.M.; Hirama, T.; Kitov, P.I.; Bundle, D.R.; Brunton, J.L. A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. J. Biol. Chem. 2002, 277, 5351-5359.
35. Lingwood, D.; Binnington, B.; Rog, T.; Vattulainen, I.; Grzybek, M.; Coskun, U.; Lingwood, C.A.; Simons, K. Cholesterol modulates glycolipid conformation and receptor activity. Nature Chem. Biol. 2011, 7, 260-262.
36. Kitov, P.I.; Bundle, D.R. On the nature of the multivalency effect: A thermodynamic model. J. Am. Chem. Soc. 2003, 125, 16271-16284.